

**CENTER FOR DRUG EVALUATION AND RESEARCH**

**ADVISORY COMMITTEE: PERIPHERAL and CENTRAL  
NERVOUS SYSTEM DRUGS ADVISORY COMMITTEE**

**DATE OF MEETING: 3/18-20/93**

**CENTER FOR DRUG EVALUATION AND RESEARCH**

**ADVISORY COMMITTEE: PERIPHERAL and CENTRAL  
NERVOUS SYSTEM DRUGS ADVISORY COMMITTEE**

**DATE OF MEETING: 3/18-20/93**

**AGENDA**

# AGENDA

## PERIPHERAL AND CENTRAL NERVOUS SYSTEM DRUGS ADVISORY COMMITTEE MEETING #34

Food and Drug Administration  
Center for Drug Evaluation and Research  
Parklawn Building  
Rockville, Maryland

### OPEN SESSION

Thursday, March 18, 1993  
8:00 A.M. to Conclusion

#### Conference Rooms D&E:

- I. 8:00 A.M. Call to Order: Welcome and Information  
Stanley Fahn, M.D.  
Chairperson  
  
Opening Comments:  
Michael A. Bernstein, M.P.H.  
Executive Secretary
- II. To Follow: Open Public Hearing
- III. To Follow: Open Session  
  
NDA 20-241 ; COGNEX® (Tacrine Hydrochloride): Safety and  
Effectiveness in use for Alzheimer's Disease.
- IIIa. **FDA Presentations:**
  - I. Overview:  
Paul Leber, M.D., Director  
Division of Neuropharmacological Drug Products [DNDP]
  2. Efficacy Review:  
Randy Levin, M.D.  
Medical Reviewer  
Neurology Drug Group [DNDP]
  3. Statistical Review:  
Nancy Smith, Ph.D.  
David Hoberman, Ph.D.  
Statistical Reviewers  
Division of Biostatistics

There will be a 15 minute coffee break after FDA presentations

**IIIb. Sponsor Presentations: Parke-Davis**

1. Efficacy Discussion and Plasma Level Data:  
Steven Gracon, D.VM  
Director of Clinical Development
2. PK-PD Models:  
Nicholas Holford, MSc, FRACP  
Professor, Dept. of Pharmacology  
University of Aucland, New Zealand
3. Safety Data:  
Mark Pierce, M.D.  
Vice President of Clinical Development

**IV. Committee Discussion/Recommendation(s):**

**V. To Follow: Closing Remarks - Information and Followup**

**FDA Invited Guests;**

Leonard Berg, M.D.  
Director, Alzheimers Disease Research Center  
Washington School of Medicine  
Box 8111- ADRC  
660 South Euclid Avenue  
St. Louis, Missouri 63105

Paul Meier, Ph.D.  
Professor of Statistics  
The University of Chicago  
Chicago, Illinois

David Drachman, M.D.  
Professor, Department of Neurology  
University of Massachusetts Medical Center  
55 Lake Avenue North, Room 55-753  
Worcester, Massachusetts 01655

Richard Mohs, Ph.D.  
Department of Psychiatry, Room 3B-50  
Veterans Affairs Medical Center  
130 W. Kingsbridge Road  
Bronx, New York 10468

Leon Thal, M.D.  
Chief Neurology Services  
Department of Neurology  
Veterans Admin. Hospital Medical Center  
3350 LaJolla Village Drive  
San Diego, California, 92161

# AGENDA

## PERIPHERAL AND CENTRAL NERVOUS SYSTEM DRUGS ADVISORY COMMITTEE MEETING #35

Food and Drug Administration  
Center for Drug Evaluation and Research  
Parklawn Building  
Rockville, Maryland

### OPEN SESSION

Friday, March 19, 1993  
8:00 A.M. to Conclusion

### Conference Rooms D&E:

- I. 8:00 A.M. Call to Order: Welcome and Information  
Stanley Fahn, M.D.  
Chairperson  
  
Opening Comments:  
Michael A. Bernstein, M.P.H.  
Executive Secretary
- II. To Follow: Open Public Hearing
- III. To Follow: Open Session  
  
PLA 92-0495 ; BETASERON® (Beta Interferon): Safety and  
Effectiveness in use for Multiple Sclerosis.
- IIIa. FDA Presentations:
  1. Introduction and Background of Interferons:  
Andrew C. Lerner, M.D., Ph.D., Chairman  
CBER, Office of Therapeutics Research and Review  
Division of Cytokine Biology, CBER, HFM-508
  2. Introduction:  
Russell Katz, M.D., Deputy Director  
Division of Neuropharmacological Drug Products [DNDP]
  3. Statistical Review:  
Jawahar Tiwari, Ph.D.  
Mathematical Statistician, HFM-215, CBER

4. Safety and Efficacy Review:  
Janeth Rouzer-Kammeyer, M.D.  
Medical Reviewer  
Neurology Drug Group [DNDP]

There will be a 15 minute coffee break after FDA presentations

IIIb. Sponsor Presentations: Chiron Corporation

1. Efficacy Issues:  
Jeffrey Latts, M.D.  
Vice President, Clinical Research and Development  
Berlex Labs.
2. MRI Data:  
Donald Paty, M.D.  
Professor and Chair, Department of Neurology  
University of British Columbia

IV. Committee Discussion/Recommendation(s):

V. To Follow: Closing Remarks - Information and Followup

Special Guest From The Biologic Response Modifiers Advisory Committee :  
[non voting member]

Frederick R. Applebaum, M.D.  
Fred Hutchinson Cancer Research Center  
1124 Columbia Street, Room M-310  
Seattle, Washington 98104

Invited guests:

Henry McFarland, M.D.  
Acting Chief, Neuroimmunology Branch, CNP, DIR, NINDS  
National Institutes of Health  
Building 10, Room 5B-16  
9000 Rockville Pike  
Bethesda, Maryland 20892

# AGENDA

## PERIPHERAL AND CENTRAL NERVOUS SYSTEM DRUGS ADVISORY COMMITTEE MEETING #36

Food and Drug Administration  
Center for Drug Evaluation and Research  
Crowne Plaza Holiday Inn  
1750 Rockville Pike  
Rockville, Maryland 20857

### OPEN SESSION

Saturday, March 20, 1993  
8:30 A.M. to Conclusion

- I. 8:30 A.M. Call to Order: Welcome and Information  
Sid Gilman, M.D.  
Acting Chairperson  
  
Opening Comments:  
Michael A. Bernstein, M.P.H.  
Executive Secretary
- II. To Follow: Open Public Hearing
- III. To Follow: Open Session  
  
NDA 20-241 ; LAMICTAL® (Lamotrigine): Safety and  
Effectiveness in use for Epilepsy.
- IIIa. FDA Presentations:
  1. Introduction:  
Russell Katz, M.D.  
Group Leader, Neurology Drug Group  
Division of Neuropharmacological Drug Products [DNDP]
  2. Safety and Efficacy Review:  
John Feeney, M.D.  
Medical Reviewer  
Neurology Drug Group [DNDP]
  3. Closing Comments:  
Russell Katz, M.D.  
Group Leader, Neurology Drug Group [DNDP]

There will be a 15 minute coffee break after FDA presentations

IIIb. Sponsor Presentations: Burrougs-Welcome

[ Presentation If Necessary ]

IV. Committee Discussion/Recommendation(s):

V. To Follow: Closing Remarks - Information and Followup

**APPEARS THIS WAY  
ON ORIGINAL**



PERIPHERAL AND CENTRAL NERVOUS SYSTEM DRUGS ADVISORY COMMITTEE  
CENTER FOR DRUG EVALUATION AND RESEARCH

CHAIRPERSON

Fahn, Stanley, M.D. 1/31/96  
Director, Dystonia Clinical  
Research Center  
Columbia University College of  
Physicians and Surgeons  
710 W. 168th Street, Room 201  
New York, New York 10032

EXECUTIVE SECRETARY

Bernstein, Michael, M.P.H.  
Division of Neuropharmacological  
Drug Products  
Center for Drug Evaluation and Research  
Food and Drug Administration (HFD-120)  
5600 Fishers Lane, Room 10B-45  
Rockville, Maryland 20857

MEMBERS

Gilman, Sid, M.D. 1/31/93\*  
Professor and Chairman  
Department of Neurology  
University of Michigan  
1335 Catherine Street  
Ann Arbor, Michigan 48109

Delgado-Escueta, Antonio, M.D. 1/31/94  
Director, Comprehensive Epilepsy  
Program  
VAMC, Wadsworth, W127B  
Building 500, Room 3405  
Wilshire and Sawtelle Boulevards  
Los Angeles, California 90073

Tempkin, Nancy R., Ph.D. 1/31/94  
Associate Professor  
Department of Neurological Surgery  
and Biostatistics, ZA-50  
University of Washington  
Seattle, Washington 98104

Heyman, Albert, M.D. 1/31/95  
Professor Emeritus  
Department of Medicine  
Division of Neurology  
Duke University Medical Center  
Box 3203  
Durham, North Carolina 27710

Oderda, Gary M., Pharm.D., M.P.H. 1/31/95  
Professor and Chairman  
Department of Pharmacy Practice  
University of Utah College of Pharmacy  
258 Skaggs Hall  
Salt Lake City, Utah 84121

Choi, Dennis W., M.D., Ph.D. 1/31/96  
Chairman, Department of Neurology  
Washington University School  
of Medicine  
660 South Euclid Avenue, Box 8111  
St. Louis, Missouri 63110

Penn, Richard D., M.D. 1/31/96  
Professor of Neurosurgery  
Rush-Presbyterian-St. Luke's  
Medical Center  
1725 W. Harrison Street  
Chicago, Illinois 60612

Shoulson, Ira, M.D. 1/31/96  
Professor of Neurology, Pharmacology,  
and Medicine  
Department of Neurology, Box 673  
University of Rochester Medical Center  
601 Elmwood Avenue  
Rochester, New York 14642

Whitehouse, Peter J., M.D., Ph.D. 1/31/96  
Director, Alzheimer Center  
Case Western Reserve University and  
University Hospitals of Cleveland  
2074 Abington Road  
Cleveland, Ohio 46106

\*Member retained until successor  
is chosen.

MARCH 1993

**APPEARS THIS WAY  
ON ORIGINAL**

**CENTER FOR DRUG EVALUATION AND RESEARCH**

**ADVISORY COMMITTEE: PERIPHERAL and CENTRAL  
NERVOUS SYSTEM DRUGS ADVISORY COMMITTEE**

**DATE OF MEETING: 3/18-20/93**

**QUESTIONS**

FOOD AND DRUG ADMINISTRATION

QUESTION LIST

PERIPHERAL AND CENTRAL NERVOUS SYSTEM DRUGS ADVISORY COMMITTEE

MEETING #34

March 18, 1993

COGNEX® (Tacrine Hydrochloride); NDA 20-070: Evaluation of Safety and Efficacy In Use.

The Division of Neuropharmacological Drug Products has reviewed the New Drug Application (NDA) submitted by Parke-Davis for COGNEX and, before forwarding a recommendation to the Office of Drug Evaluation I, the Division seeks the Committee's advise on the following question:

1. Does the accumulated evidence now available support the use that COGNEX is safe and effective in Alzheimer's Disease?

**APPEARS THIS WAY  
ON ORIGINAL**

FOOD AND DRUG ADMINISTRATION

QUESTION LIST

PERIPHERAL AND CENTRAL NERVOUS SYSTEM DRUGS ADVISORY COMMITTEE

MEETING #35

March 19, 1993

BETASERON® (interferon beta); PLA 92-0495: Evaluation of Safety and Efficacy In Use.

The Division of Neuropharmacological Drug Products has reviewed the Product License Application (PLA) submitted by Chiron Corp./Berlex Labs. and, before forwarding a recommendation to the Office of Drug Evaluation I, the Division seeks the Committee's advise on the following question:

1. Has the sponser provided sufficient evidence to support the conclusion that BETASERON is effective for the treatment of Multiple Sclerosis?
2. Has the sponser provided evidence that BETASERON is safe when used in the treatment of Multiple Sclerosis?

**APPEARS THIS WAY  
ON ORIGINAL**

FOOD AND DRUG ADMINISTRATION

QUESTION LIST

PERIPHERAL AND CENTRAL NERVOUS SYSTEM DRUGS ADVISORY COMMITTEE

MEETING #36

March 20, 1993

LAMICTAL® (lamotrigine); NDA 20-241: Evaluation of Safety and Efficacy In Use.

The Division of Neuropharmacological Drug Products has reviewed the New Drug Application (NDA) submitted by Burroughs Wellcome and, before forwarding a recommendation to the Office of Drug Evaluation I, the Division seeks the Committee's advise on the following question:

1. Has the sponser provided evidence from more than one adequate and well controlled clinical investigation that supports the conclusion that LAMICTAL is effective for the treatment of Epilepsy?
2. Has the sponser provided evidence that LAMICTAL is safe when used in the treatment of Epilepsy?

**APPEARS THIS WAY  
ON ORIGINAL**